Table 1.
The clinicopathological features of the study population for both research and validation group.
| Research group | Validation group | ||||
|---|---|---|---|---|---|
| OC (n = 94) | NHC (n = 94) | OC (n = 136) | NHC (n = 136) | BOD (n = 181) | |
| Age (year) | |||||
| Range | 21-83 | 27-83 | 16-74 | 20-83 | 20-68 |
| Mean ± SD | 54.2 ± 12.0 | 56.9 ± 12.7 | 51.9 ± 11.9 | 50.2 ± 11.6 | 35.8 ± 10.6 |
| Gender | Female | Female | Female | Female | Female |
| FIGO stage | |||||
| I-II | 3 (3.2) | 33 (24.3) | |||
| III-IV | 48 (51.1) | 77 (56.6) | |||
| Unknown | 43 (45.7) | 26 (19.1) | |||
| Histologic type | |||||
| Epithelial tumor | 55 (58.5) | 111 (81.6) | |||
| Sexual cord interstitial tumor | 3 (3.19) | 9 (6.6) | |||
| Germ cell tumor | 0(0.00) | 5(3.7) | |||
| Unknown | 35 (37.2) | 11(8.1) | |||
| Family history | |||||
| No | 90 (95.7) | 81 (59.6) | |||
| Yes | 0 (0.00) | 36 (26.5) | |||
| Unknown | 4 (4.3) | 19 (14.0) | |||
| Lymph node metastasis | |||||
| No | 6 (6.4) | 48 (35.3) | |||
| Yes | 14 (14.9) | 49 (36.0) | |||
| Unknown | 74 (78.7) | 39 (28.7) | |||
| Distant metastasis | |||||
| No | 40 (42.6) | 35 (25.7) | |||
| Yes | 14 (14.9) | 50 (36.8) | |||
| Unknown | 40 (42.6) | 51 (37.5) | |||
Abbreviations: OC: ovarian cancer; NHC: normal healthy controls; BOD:benign ovarian diseases.